By Fineline Cube 
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its investigational BTK-targeted PROTAC drug, TQB3019, for the treatment of hematological malignancies. This marks a significant milestone in the development of innovative therapies for blood cancers.
Drug Mechanism
TQB3019 is a novel PROTAC drug designed to bind to the BTK protein and E3 ubiquitin ligase, activating the ubiquitin proteasome pathway to degrade target proteins. This mechanism effectively inhibits BTK and downstream signaling, suppressing tumor growth. Preclinical studies have demonstrated significant therapeutic effects, clear mechanisms of action, and good safety, positioning TQB3019 as a promising solution to overcome resistance to traditional BTK inhibitors.
Global Innovation
TQB3019 stands out as the first product of its kind globally, highlighting Sino Biopharma’s commitment to advancing cutting-edge treatments for hematological malignancies. The approval underscores the company’s leadership in the field of protein degradation therapies.-Fineline Info & Tech